GKB Ophthalmics Ltd
Incorporated in 1981, GKB Ophthalmics Ltd is in the business of manufacture and sale of ophthalmic lenses made up of Glass and Plastic
- Market Cap ₹ 49.2 Cr.
- Current Price ₹ 97.6
- High / Low ₹ 136 / 74.1
- Stock P/E
- Book Value ₹ 40.6
- Dividend Yield 0.00 %
- ROCE -4.96 %
- ROE -13.4 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 54.7 days to 40.7 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.46% over past five years.
- Company has a low return on equity of -10.0% over last 3 years.
- Contingent liabilities of Rs.17.2 Cr.
- Promoter holding has decreased over last 3 years: -8.63%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Personal Care - Indian
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
32.21 | 31.38 | 29.85 | 31.17 | 40.65 | 37.43 | 30.47 | 25.56 | 21.34 | 27.05 | 27.73 | 31.18 | 31.08 | |
30.75 | 25.58 | 30.63 | 33.61 | 41.05 | 38.41 | 31.52 | 26.29 | 21.63 | 27.44 | 28.82 | 32.46 | 33.97 | |
Operating Profit | 1.46 | 5.80 | -0.78 | -2.44 | -0.40 | -0.98 | -1.05 | -0.73 | -0.29 | -0.39 | -1.09 | -1.28 | -2.89 |
OPM % | 4.53% | 18.48% | -2.61% | -7.83% | -0.98% | -2.62% | -3.45% | -2.86% | -1.36% | -1.44% | -3.93% | -4.11% | -9.30% |
1.25 | 1.18 | 1.72 | 23.08 | 4.11 | 1.05 | 2.62 | 1.38 | 2.33 | 1.91 | 2.09 | 2.08 | 2.07 | |
Interest | 2.88 | 2.86 | 2.49 | 1.61 | 1.26 | 1.23 | 1.39 | 1.35 | 1.34 | 1.34 | 1.50 | 1.59 | 1.65 |
Depreciation | 1.15 | 1.18 | 1.48 | 1.42 | 1.34 | 1.58 | 3.43 | 3.47 | 2.99 | 2.49 | 2.54 | 2.59 | 2.61 |
Profit before tax | -1.32 | 2.94 | -3.03 | 17.61 | 1.11 | -2.74 | -3.25 | -4.17 | -2.29 | -2.31 | -3.04 | -3.38 | -5.08 |
Tax % | -9.85% | 71.77% | -25.41% | 22.43% | 31.53% | -6.20% | -14.77% | 0.00% | -7.86% | 0.00% | -5.26% | 1.18% | |
-1.19 | 0.83 | -2.26 | 13.66 | 0.76 | -2.58 | -2.78 | -4.17 | -2.11 | -2.31 | -2.88 | -3.42 | -5.14 | |
EPS in Rs | -2.86 | 2.00 | -5.44 | 32.89 | 1.83 | -6.21 | -5.99 | -8.27 | -4.19 | -4.58 | -5.71 | -6.78 | -10.21 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 13% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 3% |
3 Years: | % |
TTM: | -35% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 15% |
3 Years: | 7% |
1 Year: | -1% |
Return on Equity | |
---|---|
10 Years: | -10% |
5 Years: | -9% |
3 Years: | -10% |
Last Year: | -13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.64 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 |
Reserves | 13.01 | 13.84 | 11.14 | 24.80 | 25.44 | 22.78 | 30.03 | 30.21 | 27.73 | 25.36 | 22.48 | 18.95 | 15.43 |
15.09 | 12.51 | 8.62 | 7.22 | 7.19 | 9.93 | 10.05 | 10.04 | 11.97 | 11.75 | 11.22 | 11.08 | 12.04 | |
19.75 | 20.67 | 24.79 | 11.36 | 10.22 | 8.57 | 10.45 | 11.40 | 12.13 | 11.74 | 10.41 | 13.32 | 15.76 | |
Total Liabilities | 52.00 | 51.17 | 48.70 | 47.53 | 47.00 | 45.43 | 55.17 | 56.69 | 56.87 | 53.89 | 49.15 | 48.39 | 48.27 |
12.67 | 13.61 | 11.72 | 12.49 | 16.43 | 16.98 | 24.29 | 24.83 | 22.28 | 21.27 | 17.28 | 15.89 | 15.29 | |
CWIP | 2.29 | 0.57 | 0.57 | 0.57 | 0.57 | 0.24 | 0.00 | 0.00 | 1.23 | 3.29 | 3.82 | 3.78 | 3.78 |
Investments | 4.23 | 5.53 | 5.53 | 10.45 | 3.77 | 0.66 | 0.32 | 3.21 | 12.22 | 11.90 | 11.90 | 11.90 | 11.90 |
32.81 | 31.46 | 30.88 | 24.02 | 26.23 | 27.55 | 30.56 | 28.65 | 21.14 | 17.43 | 16.15 | 16.82 | 17.30 | |
Total Assets | 52.00 | 51.17 | 48.70 | 47.53 | 47.00 | 45.43 | 55.17 | 56.69 | 56.87 | 53.89 | 49.15 | 48.39 | 48.27 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.97 | 5.47 | 5.87 | -11.90 | -4.20 | -3.71 | 5.31 | 6.13 | 2.11 | 2.33 | -1.14 | 1.36 | |
-1.02 | -0.65 | 0.13 | 14.74 | 5.50 | 2.28 | -8.63 | -5.68 | -11.52 | -0.83 | 2.40 | 0.37 | |
-0.95 | -4.82 | -6.00 | -2.81 | -1.29 | 1.41 | 9.21 | 3.31 | 0.61 | -1.50 | -2.03 | -1.74 | |
Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | -0.02 | 5.88 | 3.76 | -8.80 | 0.00 | -0.78 | 0.00 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 154.57 | 175.87 | 176.57 | 92.63 | 66.00 | 101.81 | 129.49 | 148.08 | 127.25 | 80.96 | 64.23 | 80.30 |
Inventory Days | 432.20 | 409.77 | 350.98 | 285.25 | 283.50 | 264.10 | 154.90 | 133.50 | 256.82 | 141.86 | 161.81 | 102.38 |
Days Payable | 208.29 | 232.25 | 362.47 | 119.63 | 106.91 | 84.89 | 171.32 | 222.98 | 251.31 | 158.86 | 139.11 | 157.83 |
Cash Conversion Cycle | 378.48 | 353.40 | 165.08 | 258.24 | 242.59 | 281.01 | 113.07 | 58.61 | 132.77 | 63.96 | 86.93 | 24.86 |
Working Capital Days | 139.72 | 128.88 | 65.66 | 152.00 | 144.02 | 190.74 | 112.60 | 86.54 | 101.26 | 51.14 | 72.26 | 40.74 |
ROCE % | 7.63% | 17.31% | -3.86% | -6.26% | -0.77% | -4.13% | -8.09% | -6.29% | 0.13% | -2.14% | -3.96% | -4.96% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Nov - Copies of newspaper cuttings of the extract of Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, …
-
Submission Of Consolidated Related Party Transaction As On September 30, 2024
14 Nov - Submission of consolidated Related Party Transactions for H1 2024.
-
Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.
14 Nov - Review report on standalone unaudited financial results.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14, 2024 To Take On Record The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.
14 Nov - GKB Ophthalmics announces Q2 FY2024 financial results.
-
Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024
30 Oct - Board meeting to discuss Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1]
a) Single Vision: 1.498 CR-39, 1.50 Blucheck, 1.56 Blucheck 1.56 DayNite, 1.56 DayNite FAST CHANGE, 1.50 Q-SHADE +, 1.50 SunSensor
b) Bifocal: 1.498 CR-39, 1.50 Blucheck, 1.56 Blucheck, 1.56 DayNite, 1.56 DayNite Fast Change
c) Progressive: 1.498 CR-39, 1.50 Blucheck, 1.56 DayNite, 1.56 DayNite Fast Change
d) Aspheric: 1.498 CR-39